Source: 22nd Century Group, Inc.
Initial focus will include cannabinoid-free cannabis for commercial
hemp industry and High levels of non-THC cannabinoids, such as CBD, for
legal medical marijuana markets.
22nd Century Group, Inc. (NYSE MKT: XXII),
a leader in tobacco harm reduction, announced today an important new
initiative in plant biotechnology: 22nd Century has entered into a new
cannabis research collaboration with strategic partner Anandia
Laboratories, Inc. (Anandia), based in Vancouver, Canada. As a part of
this research collaboration, Anandia will develop and grow cannabis
strains that express highly desirable characteristics and will lead to
exciting commercialization opportunities. Dr. Paul Rushton, 22nd
Century’s new Vice President of Plant Biotechnology, will have
responsibility for this partnership with Anandia.
The Company last year announced that Botanical Genetics, LLC (a wholly
owned subsidiary of 22nd Century Group) entered into a worldwide license
agreement with Anandia that granted exclusive rights to 22nd Century in
the United States to four genes required for cannabinoid production in
the cannabis plant. The license also granted 22nd Century co-exclusive
rights with Anandia to this proprietary technology in all countries
outside of the U.S. and Canada. Anandia retained exclusive rights in
Canada.
The proprietary technology licensed from Anandia allows for the
development of cannabis strains that demonstrate either an increase or
decrease in the production and content of all, or certain subsets of,
cannabinoids. The long-term goals of the Company’s research activities
relating to cannabis are to develop, protect and commercially produce
unique cannabis plant varieties that include high levels of non-THC
cannabinoids, such as CBD, for the legal medical marijuana markets, as
well as virtually cannabinoid-free cannabis for the commercial hemp
industry.
Jonathan Page, Ph.D., Co-Founder, CEO and Chief Scientific Officer of
Anandia – and the inventor of some of 22nd Century’s powerful
transcription factor technology in the tobacco plant – is an
internationally-recognized pioneer and leader in cannabis science who
co-led the team that first sequenced the cannabis genome and has made
fundamental discoveries about cannabinoid biosynthesis. Applying Dr.
Page’s expertise and Anandia’s patented technology, the Anandia team
will use modern plant breeding approaches and genomics to create
next-generation cannabis strains.
Dr. Page stated, “Anandia benefits from an excellent relationship with
22nd Century and we are excited to be expanding our relationship through
this research collaboration aimed at creating unique cannabis strains
with highly desirable traits that can be commercialized quickly.”
Henry Sicignano, III, President and CEO of 22nd Century explained, “In
much the same way that we enjoy a monopoly on the nicotinic biosynthetic
pathway of tobacco, our license agreement and research activities with
Anandia will facilitate 22nd Century’s control of the cannabinoid
biosynthetic pathway in cannabis throughout the U.S. market.” Mr.
Sicignano continued, “Though not directly related to our main tobacco
businesses, the exclusivity in, and control of, ‘next generation
cannabis strains’ could ultimately be worth billions of dollars to 22nd
Century.”
No comments:
Post a Comment